Evidence map›Paper›PMID 30552391›Full record

SynthesisScientific reports2018

Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials.

Amirhossein Sahebkar, Luis E Simental-Mendía, Matteo Pirro, Maciej Banach, Gerald F Watts, Cesare Sirtori, Khalid Al-Rasadi, Stephen L Atkin

Erratum issuedOpen access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
40citing papers in PubMed, 2 pooled it
4.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Lipoprotein(a): Cardiovascular Risk and Emerging Targeted Therapies.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Lipoprotein(a)-Lowering Drugs: A Mini Review.Journal of clinical medicine research · 2025
    Review
  15. Review
  16. Article
  17. Lp(a): A Rapidly Evolving Therapeutic Landscape.Current atherosclerosis reports · 2024
    Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 8 institutions in 8 countries.

Amirhossein SahebkarHalal Research Center of IRI, FDA, Tehran, Iran. saheb2000@yahoo.com.
Luis E Simental-MendíaBiomedical Research Unit, Mexican Social Security Institute, Durango, Mexico.
Matteo PirroUnit of Internal Medicine, Angiology and Arteriosclerosis Diseases, Department of Medicine, University of Perugia, Perugia, Italy.
Maciej BanachDepartment of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz, Zeromskiego 113, Lodz, Poland.
Gerald F WattsSchool of Medicine, Faculty of Health and Medical Sciences, University of Western Australia, Perth, Australia.
Cesare SirtoriCentro Dislipidemie, A.S.S.T. Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Khalid Al-RasadiDepartment of Clinical Biochemistry, Sultan Qaboos University Hospital, Muscat, Oman.
Stephen L AtkinWeill Cornell Medicine Qatar, Doha, Qatar. sla2002@qatar-med.cornell.edu.ORCID http://orcid.org/0000-0002-5887-7257
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda · ITMashhad University of Medical Sciences · IRMedical University of Lodz · PLMexican Social Security Institute · MXSultan Qaboos University Hospital · OMThe University of Western Australia · AUUniversity of Perugia · ITWeill Cornell Medical College in Qatar · QA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The aim of this meta-analysis of randomized placebo-controlled clinical trials was to assess the effect of ezetimibe on plasma lipoprotein(a) concentrations. Only randomized placebo-controlled trials investigating the impact of ezetimibe treatment on cholesterol lowering that include lipoprotein(a) measurement were searched in PubMed-Medline, SCOPUS, Web of Science and Google Scholar databases (from inception to February 26

Indexed as

AdultAgedAged, 80 and overAnticholesteremic AgentsDrug Therapy, CombinationEzetimibeFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypercholesterolemiaLipoprotein(a)MaleMiddle AgedPlacebosPlasmaRandomized Controlled Trials as TopicAnticholesteremic AgentsEzetimibeHydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)Placebos

Identifiers

PMID30552391
PMCPMC6294784
OpenAlexW2904533004

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.